| |
Tuesday, August 27, 2024 | 12pm ET / 9am PT Join us for a one-hour, comprehensive discussion on the importance of leveraging federated AI for innovative data collection in real-world research. Register now.
|
|
Today’s Big NewsAug 15, 2024 |
| By James Waldron Two and half years after it signed a $100 million biobucks deal with Aarvik Therapeutics to work on an undisclosed “novel oncology drug,” ArriVent BioPharma has decided to license the candidate—and confirmed that it’s an antibody-drug conjugate. |
|
|
|
By James Waldron Turnstone Biologics is narrowing the focus of phase 1 trials of its lead tumor-infiltrating lymphocyte, with cutaneous melanoma and breast cancer no longer in the mix. |
By Gabrielle Masson After Arrowhead cleared out work on a clinical-stage cardiovascular candidate, the company is filling the blank space with two obesity assets, both slated to enter the clinic in early 2025. |
By James Waldron Actuate Therapeutics became the latest biotech to join the Nasdaq this week with a scaled-back IPO that brought in $22.4 million. |
By Darren Incorvaia Antisense oligonucleotides, which bind to RNA and prevent them from being translated into proteins, have gained popularity in recent years as a way to treat neurodegenerative diseases. However, getting these drugs into the brain has been challenging, requiring invasive infusion directly into the cerebrospinal fluid. |
By Kevin Dunleavy,Fraiser Kansteiner The White House has revealed significantly reduced prices for 10 prescription drugs affected by the first wave of Medicare negotiations mandated by the Inflation Reduction Act, the Biden administration initiative which includes several measures designed to lower the cost of healthcare in the U.S. |
By Kevin Dunleavy Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in competition to attract patients to their respective treatments for sickle cell disease. |
By Angus Liu Incyte has expanded its graft-versus-host disease offerings beyond Jakafi. The new addition comes from Syndax Pharma-partnered axatilimab, which received FDA approval as a third-line therapy. |
By Kevin Dunleavy The FDA has approved Gilead's primary biliary cholangitis treatment Livdelzi. The drug, which was acquired in a $4.3 billion buyout of CymaBay Therapeutics six months ago, is the first inflammatory treatment launched by Gilead. |
By Fraiser Kansteiner Roughly one year since the commercial rollout of Tarsus Pharmaceuticals’ first marketed product Xdemvy, the company is touting the medicine’s debut as “one of the most successful eye care launches to date.” |
Fierce podcastsDon’t miss an episode |
| | In this week's episode of "The Top Line," we’re diving into Fierce Biotech’s annual Fierce 15 special report. |
|
|---|
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
